The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Open Access
- 1 July 2006
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 28 (1), 138-143
- https://doi.org/10.1183/09031936.06.00135905
Abstract
The treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary endarterectomy (PEA). However, many patients develop a severe progressive small vessel pulmonary arteriopathy that is inaccessible to surgical intervention and is associated with poor survival. The purpose of the present study was to evaluate the medium-term efficacy and safety of the dual endothelin receptor antagonist, bosentan, in inoperable CTEPH. Forty-seven patients with inoperable CTEPH (distal disease or persistent pulmonary hypertension following PEA) underwent evaluation after 1 yr of bosentan therapy. Outcomes included assessment of 6-min walk test (6MWT), haemodynamics and World Health Organization functional classification. Monitoring of serious adverse effects and changes in therapy was undertaken. Patients showed sustained improvements in 6MWT (49±8 m), functional classification, cardiac index (+0.2±0.07 L·min-1·m-2) and total pulmonary resistance (-139±42 dyn·s·cm-5). Those patients with persisting pulmonary hypertension following PEA showed the greatest improvement. One-yr survival was 96%, and bosentan was well tolerated with only one patient developing deranged liver function. Although all patients with chronic thromboembolic pulmonary hypertension should be considered for pulmonary endarterectomy, bosentan provides an alternative medical therapy to improve function and delay the progression of this devastating disease in those in whom surgery is not suitable.Keywords
This publication has 21 references indexed in Scilit:
- Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary EmbolismNew England Journal of Medicine, 2004
- Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertensionEuropean Respiratory Journal, 2004
- Pulmonary endarterectomy: experience and lessons learned in 1,500 casesThe Annals of Thoracic Surgery, 2003
- Effect of Orally Active Prostacyclin Analogue on Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension Without Major Vessel ObstructionChest, 2003
- Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomyThe Journal of Thoracic and Cardiovascular Surgery, 2002
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertensionHeart, 2002
- Pulmonary Vascular Lesions Occurring in Patients With Chronic Major Vessel Thromboembolic Pulmonary HypertensionChest, 1993
- Chronic thrombotic obstruction of major pulmonary arteriesAmerican Journal Of Medicine, 1963